Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Prescription Monitoring topic
No spam. Unsubscribe anytime.
Lawmaker seeks to add mifepristone to controlled-substance monitoring program; committee set for hearing
Summary
RS 32165 would classify mifepristone and mifepristol as Schedule IV controlled substances so prescriptions would be reported to the prescription drug-monitoring program; the committee introduced the request, and members asked for details on impacts to medical training and monitoring workload.
Representative Jordan Redmond presented RS 32165, which would add mifepristone and "mifepristol" (transcript spelling) to the uniform controlled substance Schedule IV list, thereby creating mandatory reporting to the state's Prescription Drug Monitoring Program (PDMP).
"Moving these drugs to schedule 4 means they get reported to the prescription drug monitoring program, so there's more oversight to ensure they aren't being abused by patients, prescribers, or pharmacies," Redmond said, adding the change is not intended to prevent medically necessary use.
Representative Healy and Representative Edelman asked whether adding these drugs would create additional revenue or monitoring burdens; Redmond said PDMP staff already handle many drugs and the addition would fit into existing work. Representative Edelman specifically asked about effects on medical students' training; Redmond said he would address that at a full hearing. The committee voted to introduce RS 32165 for a hearing.
